| iRHOM2 takes control of rheumatoid arthritis. | |
| | |
MedLine Citation:
|
PMID: 23348732 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The cytokine TNF-α is a major drug target for rheumatoid arthritis, an inflammatory joint disorder. An alternative approach is to target the protease TNF-α convertase (TACE), which releases TNF-α from cells. However, because TACE cleaves other proteins involved in development and cancer, a tissue-specific inhibition of TACE in immune cells appears mandatory. In this issue of the JCI, Issuree et al. report that iRHOM2 is a TACE activator in immune cells. Loss of iRHOM2 largely protects mice from inflammatory arthritis, making iRHOM2 a potential drug target for this condition. |
| | |
Authors:
|
Stefan F Lichtenthaler |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-25 |
Journal Detail:
|
Title: The Journal of clinical investigation Volume: - ISSN: 1558-8238 ISO Abbreviation: J. Clin. Invest. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7802877 Medline TA: J Clin Invest Country: - |
Other Details:
|
Languages: ENG Pagination: 1-3 Citation Subset: - |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ubiquitylation and the pathogenesis of hypertension.
Next Document: Old King Coal - molecular mechanisms underlying an ancient treatment for atopic eczema.